May 15, 2012 (Vol. 32, No. 10)

Wayne Pisano joined VaxInnate as president, CEO, and member of the board. Pisano had previously been president and CEO of sanofi pasteur and held various positions at sanofi since 1997. Pisano has also worked in the pharmaceutical division of Novartis (Sandoz).

Wayne Pisano

QPharma promoted Prajeep Kumar Thottupurath to CIO…Bicycle Therapeutics appointed Rolf H. Günther, M.D., Ph.D., as CEO…PTC Therapeutics promoted Claudia Hirawat to president and Mark Boulding to evp and CLO…Symphogen named Martin Olin CFO…Knome added Hugh Y. Rienhoff Jr., M.D., to its scientific advisory board and hired Charles Abdalian as CFO, Jay Therrien as head of global sales, and Adam Rosenberg as head of corporate development…Laureate Biopharma named James D. Utterback to its board of directors.

David M. Spencer, Ph.D., joined Bellicum as CSO. Dr. Spencer previously worked at Baylor College of Medicine as vice chairman of pathology and immunity. He co-invented chemical induction of dimerization, a technology used to control a range of biologic functions in cells.

David M. Spencer, Ph.D.

Orgenesis appointed Jacob BenArie as CEO, Dov Weinberg as CFO, and Sarah Ferber, Ph.D., as CSO…Avrio Biopharmaceuticals appointed William P. Botha as president…Syndax Pharmaceuticals appointed Joanna Horobin, M.D., as president…Neil L. Berinstein, M.D., Volker Diehl, M.D., Ph.D., Lindy G. Durrant, Ph.D., Adriaan Fruijtier, and Anne Tomalin are all now international members of Biovest’s scientific advisory board…GenMark Diagnostics named Richard B. Slansky CFO…Joseph F. “Joe” Woody and Lisa N. Colleran joined the board of directors of the parent company of Kinetic Concepts and LifeCell.

Arlene M. Morris is the new CEO of Syndax Pharmaceuticals. Morris had been president and CEO at Affymax for eight years prior to this appointment. Before that, she was president and CEO of advisory firm Clearview Projects.

Arlene M. Morris

InVasc Therapeutics added George L. Bakris, M.D., and Gordon H. Williams, M.D., to its scientific advisory board…Adventrx Pharmaceuticals established a regulatory advisory board that includes Frank J. Sasinowski, J.D., Cindy Dinella, Pharm. D., and Bonnie Hepburn, M.D...Intarcia Therapeutics appointed Michelle Baron, M.D., to vp, clinical research and CMO…Tonix Pharmaceuticals appointed Leland J. Gershell, M.D., Ph.D., as CFO and Bruce L. Daugherty, Ph.D., as senior director of drug development…Antoun Nabhan, J.D., joined Tobira Therapeutics as vp, business development.

EnVivo Pharmaceuticals named Christopher L. Burnley as CBO. Burnley was a founder and CEO of VetRx before this appointment. Prior to that, he served as evp and CBO and then evp and COO of Phenomix. He was also vp, business and operations of genomics at Monsanto.

Christopher L. Burnley

TapImmune appointed Robert Florkiewicz, Ph.D., as senior director of molecular biology & virology…Amicus Therapeutics named William D. “Chip” Baird, III, CFO…Ikaria appointed Joseph Stauffer, D.O., as CMO…Theorem Clinical Research named Brian Mooney svp, global clinical development and Nitin Jain vp and general manager for the Asia-Pacific region…MorphoSys nominateed Karin Eastham and Marc Cluzel, M.D., Ph.D., as new members of the supervisory board.

Joseph M. Beechem, Ph.D., is now svp, R&D at NanoString Technologies. Dr. Beechem worked at Life Technologies before joining NanoString, most recently serving as vp, head of advanced sequencing and head of global sequencing chemistry, biochemistry, and biophysics.

Joseph M. Beechem, Ph.D.

Michael A. Griffith is now on Repligen’s board of directors…IntelliCell BioSciences appointed Robert J. Sexauer as evp and Sarah R. Young as director of quality assurance…Hospira named John B. Elliot svp, operations…Array BioPharma named Howard Holden, Ph.D., vp, regulatory affairs and quality assurance…XTL Biopharmaceuticals added Ben-Zion Weiner, Ph.D., to its board of directors.

Send your People Announcements to [email protected].

Previous articleNew UMass Accelerator to Focus on Growing Biomanufacturing
Next articleScil, Ono Establish Affilin Therapeutics Discovery, Development Collaboration